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Abstract
Background: ATP-binding cassette (ABC) transporters protect cells against unrelated (toxic) substances by
pumping them across cell membranes. Earlier we showed that many ABC transporters are highly expressed in
hematopoietic stem cells (HSCs) compared to more committed progenitor cells. The ABC transporter expression
signature may guarantee lifelong protection of HSCs but may also preserve stem cell integrity by extrusion of
agents that trigger their differentiation. Here we have studied whether non-hematopoietic stem cells (non-HSCs)
exhibit a similar ABC transporter expression signature as HSCs.
Results: ABC transporter expression profiles were determined in non-hematopoietic stem cells (non-HSCs) from
embryonic, neonatal and adult origin as well as in various mature blood cell types. Over 11,000 individual ABC
transporter expression values were generated by Taqman Low Density Arrays (TLDA) to obtain a sensitivity
comparable with quantitative real-time polymerase chain reactions. We found that the vast majority of transporters
are significantly higher expressed in HSCs compared to non-HSCs. Furthermore, regardless their origin, non-HSCs
exhibited strikingly similar ABC transporter expression profiles that were distinct from those in HSCs. Yet, sets of
transporters characteristic for different stem cell types could be identified, suggesting restricted functions in stem
cell physiology. Remarkably, in HSCs we could not pinpoint any single transporter expressed at an evidently
elevated level when compared to all the mature blood cell types studied.
Conclusions: These findings challenge the concept that individual ABC transporters are implicated in maintaining
stem cell integrity. Instead, a distinct ABC transporter expression signature may be essential for stem cell function.
The high expression of specific transporters in non-HSCs and mature blood cells suggests a specialized, cell type
dependent function and warrants further functional experiments to determine their exact roles in cellular (patho)
physiology.
Background
Controversy has lasted for years regarding the role of
ATP-binding cassette (ABC) transporters in (cancer)
stem cell integrity [1-8]. Early discovery of the relation
between ABC transporters and stem cells arose from
the identification of the “side population” (SP), a stem
cell enriched fraction that can be isolated based on
ABCG2 dependent dye efflux. SP fractions have been
observed in both hematopoietic and solid tissues [2].
Later, tumor initiating cells were identified in the SP, as
indicated by ABC transporter gene expression (ABCB1
or ABCG2), chemo-resistance or tumorigenicity in vivo
[9,10]. Further studies showed that both in solid tumors
and in hematological malignancies cancer stem cells are
i n t r i n s i c a l l yr e s i s t a n tt oab r o a dr a n g eo fd r u g sa n d
exhibit elevated expression of drug resistance related
ABC transporters including ABCB1, ABCC1 and
ABCG2 [11,12]. Notably, CD34+CD38- leukemic pro-
genitors, which are ABCB1 and ABCG1 double positive
[13], are able to repopulate bone marrow in irradiated
NOD-SCID mice while the CD34+CD38+ counterparts
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ABCB1 and ABCG1 [13] have no repopulating capaci-
ties [5,14]. These findings could suggest that ABC trans-
porters contribute to maintain stem cell properties of
both normal and cancer stem cells. However, mice that
lack single ABC transporters show normal steady-state
hematopoiesis [7]. Also, approaches to enhance cyto-
toxicity during chemotherapy by inhibiting one single
transporter have been hardly successful [3]. The knock-
down or inhibition studies focused on one or a few
transporters. As the human gene encodes for 49 ABC
transporters, functional redundancy may preserve stem
cell integrity and chemoresistance following abrogation
of the function of one or several transporters.
Recently, we determined the ABC transporter expres-
sion signature of hematopoietic stem cells (HSCs) [13].
A large set of ABC transporters was highly expressed in
both normal and malignant HSCs compared to more
committed progenitors [13]. Thus, the absence of
obvious (stem cell) phenotypes following disruption of
one or more ABC transporters may be caused by rela-
tively high expression of other transporters. In this study
we aimed to investigate whether other non-related stem
cells exert a similar ABC transporter signature as HSCs
and profiled transporter expression in human non-HSCs
including unrestricted somatic stem cells (USSCs),
mesenchymal stem cells (MSCs), embryonic stem cells
(ESCs) and multipotent adult progenitor cells (MAPCs).
To compare the expression signatures with differentiated
cells we also analyzed human mature blood cell types. To
obtain maximal detection sensitivity over a large range of
expression levels, Taqman Low Density Arrays (TLDA)
were employed to determine gene expression [13,15].
Methods
Human non-HSCs and mature blood cells
H u m a nc o r db l o o dd e r i v e dU S S C s( n=6 )w e r eg e n e r -
ated and differentiated towards the osteogenic lineage as
described [16,17]. Mature human blood cells were
obtained from normal bone marrow or peripheral blood
by Ficoll gradient centrifugation (granulocytes) or by
fluorescence activated cell sorting with specific cell sur-
face markers to gain a purity above 95%: CD3+
(T cells), CD56+CD3- (NK cells), CD14+ (monocytes),
CD71+ (erythroid progenitors) as described previously
[18,19]. Total mRNA was subsequently isolated using
RNABee (Bio-Connect BV, the Netherlands). mRNA of
human MSCs derived from adult adipose tissue (n = 3)
and bone marrow (n = 4) was kindly provided by Dr. E.
Piek, Department of Applied Biology and Dr. B. Jansen,
Tumor Immunology Laboratory, Radboud University
Nijmegen Medical Center, the Netherlands [20]. mRNA
of human bone marrow derived MAPC lines (n = 3)
was provided by Dr. C. Verfaillie, Leuven. The mRNA of
three hESC cell lines (HUES1, HES2, and HES3), origi-
nating from Douglas Melton’s Lab (HUES1) and ES Cell
International, Singapore http://www.escellinternational.
c o m( H E S 2a n dH E S 3 ) ,w e r ek i n d l yp r o v i d e db yP r o f .
Dr. C. Mummery, Department of Anatomy and Embry-
ology, Leiden University Medical Centre, the Nether-
lands. Transporter expression profiles in HSC samples
(n = 11) that we observed earlier [13] were taken as
reference for comparisons with the profiles in non-
HSCs and mature blood cell types.
TaqMan Low Density Array
First strand cDNA of the mRNA samples indicated
above was synthesized using reverse transcriptase as
described (Invitrogen) [19]. Gene expression profiles
were assessed by quantitative real-time RT-PCR using
micro fluidic cards (Taqman Low Density Arrays,
TLDA, Applied Biosystem), covering 45 transmembrane
ABC transporters and three housekeeping genes
(GAPDH, HPRT1 and HMBS) as described earlier [13].
The expression levels were calculated relative to
GAPDH (Additional file 1: TLDA data table on all the
studied cell types).
Statistical analyses
Over 11,000 ABC transporter expression values were
generated by TLDA. Some transporter genes were
expressed at very low levels around the detection limit,
introducing unwanted disturbance in statistical analyses.
To avoid this, the highest mean expression level in the
HSCs (6.65E-02, observed for ABCA2 in HSCs samples)
was divided by 1000 (6.65324E-05) and used as back-
ground level. Expression values below the background
level were replaced by this threshold. In this way the
noise caused by the variation in extremely low values was
abolished. Principal component analysis (PCA) [21,22]
was performed using Partek Genomic Suite 6.4 to iden-
tify outliers in our sample sets and to investigate similari-
ties of samples based upon the cell types. Unsupervised
hierarchical clustering was performed by using Partek
Genomic Suite 6.4 to visualize genes defining different
cell types and to determine the similarity/distance
between the studied cell types. We used the Pearson dis-
similarity as a distance measure. Differential expression
was examined by a non-parametric Mann-Whitney
U-test in Partek Genomic Suite 6.4. Genes with P-values
< 0.05 after multiple testing correction by bootstrapping
were deemed significantly differentially expressed.
Results
Non-HSCs show striking similarities in ABC transporter
expression profiles clearly distinct from HSCs
Earlier we showed that a broad range of ABC transpor-
ters was highly expressed in HSCs compared to more
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Page 2 of 9committed progenitor cells [13]. To determine the rele-
vance of this finding, we measured by TLDA transporter
expression profiles in non-HSCs including USSCs,
MSCs, MAPCs and ESCs. Striking to note is that non-
HSCs, regardless their origin, exhibited a remarkable
similarity in transporter expression clearly distinct from
that observed in HSCs (Fig. 1 A). Unsupervised hier-
archical cluster analysis confirmed the strong similarity
among non-HSCs. The 11 HSC samples clustered
together, with a distinguishable distance to other stem
cell types (Fig. 1 B). MAPCs and ESCs also clustered in
separate groups while USSCs and MSCs fell into one
and the same group, suggesting that MSCs and USSCs
are closely related (Fig. 1 B). Principal component analy-
sis (PCA) verified the resemblance among non-HSCs
(Fig.1 C). Among the HSC samples a larger relative
distribution was observed as compared to non-HSCs,
indicating that differences within HSC samples are
greater than those among other stem cells. Another
important observation is that most transporters showed
higher expression in HSCs than in other stem cell types,
except for ABCA1, ABCB6, ABCB8 and ABCD3, which
were similarly expressed in both HSCs and non-HSCs
(Fig. 1 A). The mean expression values of ABCB1 and
ABCG1 were more than 1000-fold higher in HSCs while
the other genes about 10-fold higher. Interestingly, some
Figure 1 Non-HSCs show striking similarity in ABC transporter expression profiles clearly distinct from HSCs. (A) TLDA expression data
plot. The expression levels relative to GAPDH are shown in log-scale, plotted against the ABC transporter genes ranked in descending order by
expression levels in 11 CD34+38- HSC samples. The expression profile of CD34+38- HSCs here serves as reference [13]. The transporters are
further divided into two groups (left and right) according to the detection frequency (whether above 10/11) in the HSCs. Count of detectable
samples out of the 11 reference HSC samples is indicated on the top of the figure for each transporter. Transporters genes in the right part are
ranked first by detection frequency and then by the expression level. The error bars show the standard deviations. In this plot the background
threshold applied for unsupervised hierarchical clustering and PCA was not used. (B) Unsupervised hierarchical clustering allowing a separation
between HSCs and non-HSCs based on ABC transporter expression profiles. Red and blue indicate high and low expression, respectively. (C) PCA
of HSCs and non-HSCs based on ABC transporter expression profiles verified the resemblance among non-HSCs. This PCA mapping represents
68.1% of gene expression information. (D) Detection frequency of each transporter gene in HSCs, MSCs and USSCs. Note that some transporters
are detected in all studied USSCs and MSCs but not in HSCs (e.g. ABCA4 and ABCC9).
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ABCG4, were scarcely detectable in HSC samples
whereas they were consistently detected in USSCs and
MSCs (Fig.1 A and 1D).
To identify genes representative for each stem cell
type, we performed Mann-Whitney U-tests. Sixteen
genes defined HSCs from non-HSCs (Additional file 2:
Genes defining HSCs from other stem cells). Amongst
these genes some are known to be implicated in hema-
topoiesis, such as ABCB1 and ABCG1 [2,4,5,23]. Nota-
bly, ABCB1 is the gene to distinguish HSCs with the
highest fold difference in median value (1.41E + 04
fold). Nevertheless, other transporter genes with no
described hematopoietic functions, like ABCA3, ABCA5,
ABCA7 and ABCD4, also discriminate HSCs from non-
HSCs.
Despite the strong similarity regarding transporter
expression in non-HSCs, distinct sets of ABC transpor-
ter genes could be identified typifying each non-HSC
source by Mann-Whitney U-tests (Additional file 3:
Combination of ABC transporter genes unique for each
subgroup of cells). Interestingly, some transporters not
reportedly related to stem cell functions were signifi-
cantly higher expressed in ESCs compared to other
non-HSCs, such as ABCA3, ABCA7 and ABCC8.
ABCG2 was differentially higher expressed in the ESC
samples we studied and the expression of ABCA8 and
ABCC9 was about 1000-fold lower in ESCs than in
other non-HSCs. MAPCs were highlighted by ABCA13
with an expression level about 60-fold higher than in
other non-HSC sources. MSCs also showed differential
expression of several transporters while for USSCs only
one differentially expressed transporter (ABCD4) was
observed (Additional file 3). In summary, non-HSCs
exhibited strikingly similar ABC expression profiles
remarkably distinct from those in HSCs and HSC exhib-
ited overall higher expression levels compared to non-
HSCs. Characteristic sets of transporters in HSCs and
different non-HSCs were identified, suggesting that spe-
cific combinations of transporters are important for the
physiology of non-related stem cells.
ABC transporters are not down modulated following
osteogenic differentiation of USSCs
We have shown that ABC transporter expression was
down modulated during the differentiation of both nor-
mal and leukemic HSCs [13]. Besides, we recently
observed that some miRNAs were down regulated fol-
lowing osteogenic differentiation of USSCs [17]. These
findings prompted us to study whether ABC transporter
expression decreases following USSC differentiation.
However, transporter profiling by TLDA did not reveal
broad down regulation as observed in the initial steps of
HSC maturation. On the contrary, some transporters
were even induced (Fig. 2). This suggests that ABC
transporters may serve a different function in USSCs
compared to HSCs.
Mature blood cells exhibit higher expression of specific
transporters compared to HSCs
The substantial expression of a broad range of ABC
transporters compared to non-HSCs and committed
progenitors may indicate that they play an important
role in HSC biology. The implication of these transpor-
ters in HSC maintenance may be also inferred by their
down regulation during early steps in HSC differentia-
tion [13]. To study this issue in more detail we mea-
sured transporter profiles in various mature blood cell
types including monocytes, granulocytes, CD71+ ery-
throid progenitors, T cells and NK cells in order to
determine whether the high expression is unique to
HSCs. Unexpectedly, most transporters were expressed
at a higher level in at least one of the mature blood cell
t y p e sr a t h e rt h a ni nH S C s( F i g .3 Aa n d3 B ) .F o r
instance, in T cells, NK cells and granulocytes the
expression of ABCA7, ABCB2 and ABCB3 was above
10-fold higher than in HSCs. The expression of ABCD2
in T cells was evidently elevated in comparison with any
other blood cell fraction. ABCB1, a gene with widely
reported relevance to stem cells, exhibited in NK cells
an expression level exceeding that in HSCs. Cholesterol
transporter ABCA1 and lipid transporter ABCA2 were
evidently higher expressed in granulocytes and NK cells,
respectively, compared to HSCs. Likewise, the expres-
sion of ABCB6 and ABCB10 and ABCG2 in CD71+ ery-
throid progenitors was more than 40-fold above that in
HSCs. The highest expression level of all the studied
cell types was observed for ABCB10 in CD71+ erythroid
progenitors. Unlike other transporters, ABCA13 and
ABCC1 showed slightly higher expression in HSC sam-
ples compared to all mature blood cell types (less than
2-fold higher compared to granulocytes and T cells)
(Fig. 3A and 3B). Consistent with the TLDA plots
(Fig 3AB), unsupervised hierarchical clustering pre-
sented higher expression levels mostly in more mature
blood cell samples (Fig. 3C). HSC samples fell into a
distinct group apart from mature blood cell types in
both unsupervised clustering and PCA. Characteristic
expression patterns evidenced by separated clusters were
observed for each different mature blood cell fraction
except for monocytes and granulocytes, which fell into
one and the same group in unsupervised hierarchical
cluster analysis (Fig. 3C and 3D). Of note, the CD71+
erythroid progenitor samples constituted a tight cluster
in PCA, identifying these samples as a highly homoge-
nous and specialized cell type (Fig. 3D). Differential
gene expression through subgroups of mature blood cell
fractions was determined by a Mann-Whitney U-test as
Tang et al. BMC Pharmacology 2010, 10:12
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identified in NK cells and CD71+ erythroid progenitors.
ABCB1 was found to represent NK cells; so were
ABCB6, ABCB10 and ABCG2 representative for ery-
throid progenitors.
Discussion
A remarkable finding of this study is that non-HSCs from
adult, neonatal or embryonic origins exhibit a very simi-
lar ABC transporter expression profile that is clearly dif-
ferent from HSCs (Fig. 1 A, B and 1C). Apparently HSCs
rely on a different repertoire of transporters whereas for
other stem cells it is more similar. Three separate clusters
can be seen in Fig. 1 B for MAPCs, ESCs and USSCs/
MSCs, despite the strong resemblance regarding trans-
porter expression in non-HSCs. Although USSCs differ
from MSCs with respect to telomere length, immunophe-
notype and differentiation potential [16], they fell into
one and the same cluster in unsupervised hierarchical
cluster analysis based on transporter expression profiles
(Fig. 1 B). This indicates a close similarity between
USSCs and MSCs. Nevertheless, comparison of profiles
among non-HSCs revealed differential transporter
expression, especially for MAPCs and ESCs (Additional
file 3). ABCA13 was representative for MAPCs by an
expression level about 60-fold higher compared to other
non-HSC sources. ABCA13 is expressed in human hip-
pocampus and cortex and rare variants in this gene have
been associated with neurological disorders [24]. Since
ABCA family members share a cholesterol efflux related
C-terminal motif, the function of ABCA13 might be lipid
related as well [25]. It may explain a role for ABCA13 in
neurological disorders since lipid shuttling across cell
membranes is crucial to intracellular signalling pathways
and neurotransmitter functions. This might imply that
MAPCs rely more on lipid metabolic pathways than
other non-HSCs do. Of note, ABCG2, a transporter of
intense debate regarding its expression in human ESCs
[8,26], was expressed at significantly higher levels in the
ESC samples studied here compared to other non-HSCs
(Fig. 1). This is in agreement with the study of Sarkadi et
al [26]. As a principal multidrug resistant gene
[1,2,4,27-31], ABCG2 can potentially protect undifferen-
tiated ESCs against the damage caused by toxins or
hypoxia. Specific roles in human disorders or physiologi-
cal functions for several other transporters that are differ-
entially expressed through non-HSC samples (Additional
file 3) have been reported [32-36]. Further research on
their exact function in stem cells is warranted.
Another important finding here is that out of the 23
most frequently detected and highly expressed transpor-
ters in HSCs, the majority showed lower expression in
non-HSCs (Fig. 1A). Mann-Whitney U-test revealed 16
transporters to be expressed at significantly higher levels
in HSCs compared to other stem cells (Additional file
2). Out of these 16 transporters, the expression of
ABCB1 and ABCG1 was above 1000-fold higher in
HSCs. The role of ABCB1 in bone marrow repopulation
capacity and chemoresistance has been intensively stu-
died and widely reported [1,4,5,28,37,38]. ABCG1 has
been shown to regulate proliferation of hematopoietic
stem cells through high-density lipoprotein [23,39].
ABCG2, one of the major multidrug transporters
[1,2,4,27-31], is not consistently detectable in HSCs,
which is in agreement with a recent report showing that
ABCG2 expression is not correlated to hematopoietic
Figure 2 ABC transporters are not down modulated following osteogenic differentiation of USSCs. The expression levels on day 0 are set
at 1 and the fold difference in expression at other time points is given on day 1, day 3 and day 7. Significant threshold is 3-fold induction or
downregulation and is indicated by the grey lines. Detection count of each gene in 6 USSC samples is indicated on the bottom of the figure for
each transporter. Only transporters with detection frequency above 5/6 in USSCs are included.
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Page 5 of 9Figure 3 Mature blood cells exhibit higher expression of specific transporters compared to HSCs. (A) (B) TLDA expression data plot. The
layout of the plot is as described in the legend of figure 1 A. (C) Unsupervised hierarchical clustering of HSCs and mature blood cell types
based on ABC transporter expression profiles. (D) PCA of HSCs and mature blood cell types based on ABC transporter expression profiles. This
PCA mapping represents 80.2% of gene expression information.
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entially expressed genes (above 10-fold higher) have not
been reported to have immediate relevance to hemato-
poiesis, such as ABCA3, ABCA5, ABCA7 and ABCD4.
These genes might be involved in lipid transport or
intracellular trafficking of peroxisomes or lysosomes
[32-34,40-42]. Lipid redistribution is required for polari-
zation of HSCs, which is essential to initiate migration,
hence lipid transporters (such as ABCA3 and ABCA7)
may potentially influence HSC migration [31]. A few
transporters, including ABCA1, ABCB6, ABCB8 and
ABCD3, were similarly expressed in both HSCs and
non-HSCs but still at a lower level compared to mature
blood cell types. Notably, a set of transporters was con-
sistently detected in MSCs and USSCs but scarcely
detectable in HSCs, including ABCA4, ABCA8, ABCC9
a n dA B C G 4( F i g .1D ) .A B C A 4 ,A B C A 8a l o n gw i t h
ABCG4 might play a role in brain lipid transport [42]
and ABCC9 constitutes the regulatory subunit of an
ATP-sensitive potassium channel [43,44]. These four
transporters were not significantly expressed in mature
blood cell types either, representing a specific signature
of non-HSCs.
To further study the relevance of the finding that a
broad range of transporters exhibited higher expression
levels in HSCs compared to non-HSCs we analyzed
mature blood cell types. It was observed that only
ABCA13 and ABCC1 were slightly higher expressed in
HSCs than in mature blood cell types. As discussed
above, ABCA13 might play a role in lipid redistribution
[24,25,31]. As HSC polarization is accompanied by
redistribution of transmembrane lipid rafts and a polar-
ized morphology is required for cells to initiate migra-
tion [31], it will be interesting to investigate whether
ABCA13 contributes to HSC migration. ABCC1 is
known to be involved in chemoresistance of hematologi-
cal cancer stem cells [11,12], however it is not obviously
down regulated throughout differentiation, questioning
its contribution to stem cell integrity. Actually most
transporters showed evidently higher expression in
developed blood cell types (Fig. 3A,B and 3C), challen-
ging the concept that individual transporters may func-
tion in maintaining stem cell integrity [1,2,4,5]. For
instance, outstanding high expression levels were
observed for ABCB2 and ABCB3 in granulocytes, T cells
and NK cells (Fig. 3A and 3B). ABCB2 (TAP1) and
ABCB3 (TAP2) belong to the transporter associated
with antigen processing (TAP) family, which is crucial
for the adaptive immune system. TAP translocates pro-
teasomal degradation products into the endoplasmic
reticulum, in order to present them to the major histo-
compatibility complex (MHC) I molecules [45]. This
suggests an association of the high expression of ABCB2
and ABCB3 with their specific immunological function
in T cells and granulocytes. In CD71+ erythroid pro-
genitors the expression of ABCB6, ABCB10 and ABCG2
was extremely high in comparison with HSCs and other
mature blood cell types. These transporters have been
implicated in porphyrin transport and/or heme
biosynthesis, which explains their high expression in
haemoglobin synthesizing cells[46-51]. Given that
mature blood cell types exhibit higher transporter
expression compared to HSCs, it will be important to
compare transporter expression signatures in tissues
derived from non-HSCs.
Conclusions
Here we identified specific ABC transporter expression
signature in non-HSCs compared to HSCs. Four trans-
porters, ABCA4, ABCA8, ABCC9 and ABCG4, are of
special interest since they are expressed in non-HSCs
b u th a r d l yd e t e c t a b l ei nH S C so rm a t u r eb l o o dc e l l s .
The high expression of several transporters in com-
mitted blood cells challenges the concept that individual
ABC transporters may maintain stem cell integrity by
protecting them against xenobiotics [1,2,4,5]. Instead, a
distinct ABC transporter expression signature might be
essential for stem cell function rather than overexpres-
sion of single transporters. These findings warrant
further studies on specific transporters in different cell
types.
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